• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Advocacy

Harnessing AI & new technologies for pharmaceutical R&D

To accelerate drug development for neglected diseases

Home > Advocacy

Harnessing AI & new technologies for pharmaceutical R&D

To accelerate drug development for neglected diseases

Digitalization, machine learning, artificial intelligence (AI), and new technologies and platforms are bringing transformational benefits to the fields of medicine, pharmaceutical research, and public health. We are working to ensure these benefits extend to the most neglected.

Accelerate the pharmaceutical R&D process with cutting edge technology

DNDi is committed to employing new technologies to improve the efficiency and accelerate the pace of the R&D process, including AI-driven drug discovery tools; novel imaging, diagnostic, and clinical trial design and operations technologies; and AI-driven data analysis.

Partnerships with leading AI companies are already bearing fruit. DeepMind is a British AI company whose scientists and engineers are at the forefront of using AI to address a challenge that has confounded biologists for 50 years: how to predict the shape of a protein using the amino acids that constitute it. Proteins are the building blocks of life – and disease – and the ability to predict their structures has profound implications for drug discovery and development. In 2021, our discovery team was invited to trial the software to overcome a puzzling challenge that was impossible to address with standard laboratory methods – and the research breakthrough could help speed up the development of a promising treatment for leishmaniasis.

Implement eHealth solutions to strengthen data collection

In addition to exploring the use of new technologies in the drug discovery and development process, we are also expanding our use of eHealth solutions at our trial sites to strengthen data collection, processing, and analysis, and improve patient safety while managing associated risks, particularly in the areas of privacy and the protection of patients and personal data.

Best practices in data collection are yielding results in Eastern Africa where the Data Management and Biostatistics Centre, established in Nairobi, Kenya, in 2004 helps to run studies in remote areas in the region, as well as providing a vital service to other organizations through data management and statistical analysis for clinical trials throughout the region. The Centre adopted an electronic data capture system to retrieve data in real time from clinical trial sites for faster review, analysis, and sharing, and since its inception, has managed data for over a dozen clinical trials for leishmaniasis, multidrug-resistant tuberculosis, paediatric HIV, Buruli ulcer, and mycetoma – including with partner organizations such as the World Health Organization, Médecins Sans Frontières (MSF), and the Kenya Medical Research Institute.

Consider host targeted therapies and biologics for the treatment of neglected diseases

DNDi is committed to exploring host targeted therapies as alternative or complementary therapeutic options to single antimicrobial regimens, as well as the potential of fast-evolving therapeutic modalities beyond small molecule drugs – for example, messenger ribonucleic acid (mRNA) therapeutics, monoclonal antibodies, and other biologics – that hold promise for the treatment of DNDi target diseases.

CpG-D35, an immunomodulator, is currently being explored as a booster to current treatments for cutaneous leishmaniasis. Find out more about CpG-D35

News & resources on AI & new technologies

Loading…
filter by
ALL
News
In the media
Press releases
Publications
NHK logo
In the media
18 Jan 2025

Drugmakers tap AI to develop new treatments

NHK
NHK logo
In the media
13 Dec 2024

“顧みられない熱帯病” 治療薬開発でAIに期待 研究開発機関

NHK
Computer screen
News
10 Oct 2024

Nobel prize for chemistry awarded to Demis Hassabis and John Jumper for AlphaFold, an AI model used by DNDi for neglected diseases

Nature logo
In the media
23 Aug 2024

Partners in drug discovery: how to collaborate with non-governmental organizations

Nature
See all news

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License